Abstract
The ROX CONTROL HTN study demonstrated the efficacy of arteriovenous coupler therapy in patients with resistant hypertension. However, one-third of the patients developed late ipsilateral venous stenosis, which required venoplasty or stenting. Future research is needed to identify the risk–benefit ratio of this new approach.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have